NuvOx Therapeutics Inc. (NUOX) IPO — Expected Date, Price Range & Deal Size

NuvOx Therapeutics Inc. (NUOX)

This company has not started trading yet. The live 5-factor QL signal switches on automatically on its first session.

About NuvOx Therapeutics Inc.

We are a clinical -stage biopharmaceutical company developing innovative oxygen therapeutic solutions for the treatment of diseases where hypoxia, or lack of oxygen, plays a critical role. Our product candidate is NanO 2 , the API of which is dodecafluoropentane.

From NuvOx Therapeutics Inc.'s Form S-1/A filed with the SEC on 2026-09-16. The issuer's own words — QuantLogix does not paraphrase it.

Industry

Pharmaceutical Preparations

Headquarters

Tucson, AZ

Incorporated in

Delaware

Fiscal year ends

December 31

SEC filer

CIK 0001966126

The offering

Ticker

NUOX

Exchange

XASE

Expected listing

To be announced

Offer price

Deal size

$23M

gross proceeds

Shares offered

2,860,000

Shares outstanding

13,268,218

after the offering

Implied market cap

$106M

at the final offer price

Public float

21.6%

of shares outstanding

Share class

Ordinary Shares

Financials, as filed

The audited financial statements for this issuer are in its Form S-1/A filed 2026-09-16. QuantLogix only publishes figures it can read directly from the filing.

QL Listing Score — the prospectus, scored

26/100

Distressed · low confidence

The evolution of the private-company QL Score at the point of listing: four evidence pillars read deterministically from the registration statement — growth, revenue quality, technology and risk — weights frozen per version (v1.1.0), pillars with no evidence excluded and reweighted, never defaulted.

Growthno evidence — excluded

Revenue qualityno evidence — excluded

Technology54

technology-language density 4.6/10k words (lexical indicator, not a technical audit)

Risk15

auditor states substantial doubt about going concern · material weakness in internal controls disclosed

Foundationno evidence — excluded

⚠ Going-concern doubt disclosed⚠ Material weakness in controls✓ Single share class✓ No customer-concentration flag◆ Emerging growth company (reduced disclosure)

From NuvOx Therapeutics Inc.'s Form S-1/A filed with the SEC on 2026-09-16. Extraction is deterministic — the same filing always produces the same score; 318k characters of the document were scanned. Technology signals are lexical indicators, not a technical audit. Not investment advice; the debut itself will be this score's first grade.

Deal terms come from the public IPO calendar and change up to pricing — an expected date reads “to be announced” until the underwriters set it, and a range is not a final price. Implied market cap and float are arithmetic on those disclosed terms. Nothing on this page is a forecast or a recommendation.